Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc HMTXF


Primary Symbol: V.HEM

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Announces $2,675,981 Private Placement Including Second Tranche of $833,258

Newsfile 10 hours ago

Hemostemix Announces ACP-01 Treatment-Purchase Available with Social Media Campaign Underway

Newsfile 3 days ago

Hemostemix Announces the First Tranche Closing of $1.8M of Its Recently Announced Private Placement

Newsfile October 31, 2024

Hemostemix's Private Placement

Newsfile October 11, 2024

Canadian Investment Regulatory Organization Trade Resumption - HEM

Canada NewsWire August 2, 2024

Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01

Newsfile August 1, 2024

Canadian Investment Regulatory Organization Trading Halt - HEM

Canada NewsWire August 1, 2024

Hemostemix Announces Trademark Granted by Switzerland and Interest Payment

Newsfile June 11, 2024

Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments

Newsfile June 3, 2024

Hemostemix Announces Engagement of Oak Hill Asset Management Inc.

Newsfile March 7, 2024

Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences

Newsfile February 6, 2024

Hemostemix Clarifies its October 3, 2023 News Release

Newsfile December 29, 2023

Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease

Newsfile October 30, 2023

Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000

Newsfile October 23, 2023

Hemostemix Closed $320,125 Private Placement

Newsfile October 3, 2023

Hemostemix Announces Private Placement

Newsfile September 27, 2023

Hemostemix Announces New Publication: How NCP-01 Supports Brain Computer Interfaces

Newsfile September 12, 2023

Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications

Newsfile August 29, 2023

Hemostemix Announces Arbitration Award of CAD $315,684 Plus Private Placement

Newsfile August 14, 2023

Hemostemix Submits Its Retrospective Heart Study to Leading Stem Cell Journal and Has Prepared Its CLI Phase II Clinical Trial Manuscript for Peer Review

Newsfile August 8, 2023